Tirzepatide prevents neurodegeneration through multiple molecular pathways

Area of Science:

• Neuroscience
• Endocrinology
• Molecular Biology

Background:

• Glucagon-like peptide 1 receptor agonists (GLP1-RAs) are known to reduce dementia risk in type 2 diabetes.
• Tirzepatide (TIR) is a dual glucose-dependent insulinotropic polypeptide receptor agonist (GIP-RA)/GLP-1RA with potential neuroprotective properties.

Purpose of the Study:

• To investigate the molecular mechanisms behind TIR's protective effects against learning and memory disorders.
• To elucidate TIR's impact on neuronal growth, apoptosis, differentiation, and insulin resistance markers.

Main Methods:

• Assessed effects of TIR on neuronal markers (CREB, BDNF, BAX/Bcl2, pAkt, MAP2, etc.) in SHSY5Y cells under normal and high glucose.
• Investigated TIR's role in DNA methylation and specific miRNAs (34a, 212, 29c).
• Measured cell proliferation using Ki-67 via flow cytometry.

Main Results:

• TIR activates the pAkt/CREB/BDNF pathway, demonstrating significant neuroprotective efficacy.
• TIR effectively counteracts the detrimental effects of hyperglycemia and insulin resistance at the neuronal level.
• TIR influences epigenetic modulators and promotes cell proliferation.

Conclusions:

• Tirzepatide ameliorates high glucose-induced neurodegeneration and neuronal insulin resistance.
• This study provides novel insights into TIR's potential for managing diabetes-related neuropathy and cognitive decline.